Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19
Trial details
- Registry ID
- NCT04412668
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19NCT04412668 | ATYR | Phase 2 | Completed | 2020-10-23Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |